Expanding Product Portfolio HiberGene Diagnostics has a growing range of molecular diagnostic tests for infectious diseases, including COVID-19, meningococcus, GBS, and Mycoplasma pneumoniae, indicating opportunities to cross-sell and bundle tests for diverse clinical settings.

Regulatory Achievements With recent CE Marking approvals for combined COVID-19 and Flu tests, the company is positioned to expand into broader markets requiring regulatory certified rapid diagnostics, offering sales prospects in EU healthcare systems.

Unique Technology Advantage Utilizing LAMP technology allows HiberGene to deliver rapid, accurate, and cost-effective testing solutions, appealing to hospitals and laboratories seeking reliable point-of-care diagnostics with quick turnaround times.

Recent Funding Boost The company’s recent €1 million EU investment and $6.4 million funding demonstrate financial backing for expansion efforts and product development, creating sales opportunities through increased production and market penetration.

Strategic Collaborations Partnerships with research institutions like Queen’s University Belfast and hospitals in Europe position HiberGene for collaborative sales opportunities, especially in academic and healthcare research markets seeking rapid diagnostic solutions.